Vanguard Group Inc Salarius Pharmaceuticals, Inc. Put Options Transaction History

Vanguard Group Inc

  • $4.96 Trillion
  • Q1 2024

Put Options

0 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
No transaction found.

About Salarius Pharmaceuticals, Inc.

SLRX Quotes by TradingView
  • Ticker SLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,244,650
  • Market Cap $5.43M
  • Description
  • Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...
More about SLRX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email